Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease.

Project Information

CARBALIVE

Grant agreement ID: 634579

DOI 10.3030/634579

Project closed

EC signature date 7 April 2015

Start date 1 May 2015

End date 31 January 2021

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 9 579 686,54

EU contribution € 5 913 079,75

Coordinated by

UNIVERSITY COLLEGE LONDON
United Kingdom

Deliverables

Other (1)

Project website and social media accounts

Project website established allowing public access to non-confidential information about the CARBALIVE project.

Publications

Peer reviewed articles (2)

The gut-liver axis in liver disease: Pathophysiological basis for therapy

Author(s): Agustín Albillos; Andrea de Gottardi; María Rescigno
Published in: Journal of Hepatology, Issue 1, 2020, ISSN 1600-0641
Publisher: Elsevier
DOI: 10.7892/boris.148408

Targeting the gut-liver axis in liver disease

Author(s): Reiner Wiest, Agustin Albillos, Michael Trauner, Jasmohan S. Bajaj, Rajiv Jalan
Published in: Journal of Hepatology, Issue 67/5, 2017, Page(s) 1084-1103, ISSN 0168-8278
Publisher: Elsevier BV
DOI: 10.1016/j.jhep.2017.05.007